Srujana Mohanty

Dr. Srujana Mohanty

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2009 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
SMSrujana Mohanty
Srujana Mohanty
RGRajni Gaind
Rajni Gaind
RRRajeev Ranjan
Rajeev Ranjan
MDMonorama Deb
Monorama Deb
Background: Extended-spectrum beta-lactamases (ESBLs) may not always be detected in routine susceptibility tests. This study reports the performance of the cefepime-clavulanate ESBL Etest for the detection of ESBLs in Enterobacteriaceae, including those producing AmpC enzyme. Methodology: Consecutive non-duplicate isolates of Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolated from bloodstream infections from January to June 2008 were tested for ESBL by both the standard CLSI double-disk diffusion method using ceftazidime and cefotaxime disks and Etests using ceftazidime/ceftazidime-clavulanate, cefotaxime/cefotaxime-clavulanate and cefepime/cefepime-clavulanate gradients. Isolates were also tested for the presence of transferable AmpC beta-lactamase by AmpC disk test and the efficacies of the different Etests in detecting ESBL production were compared. Results: A total of 113 bacterial isolates (61 K. pneumoniae, 50 E. coli, and 2 P. mirabilis) were recovered. Respectively, 42 (37.2%) and 55 (48.7%) isolates were positive for ESBL by the ceftazidime-clavulanate and cefotaxime-clavulanate combined disk tests. The cefepime/cefepime-clavulanate Etest strip detected the maximum number of isolates (70/113, 61.9 %) as ESBL-positive compared to the ceftazidime/ceftazidime-clavulanate and cefotaxime/cefotaxime-clavulanate strips, which detected 57 (50.4%) isolates each as ESBL-positive. All three ESBL Etest strips were equally effective in detecting ESBL in the isolates that were AmpC negative. In the 66 (58.4%) isolates that co-produced AmpC in addition to the ESBL enzymes, cefepime/cefepime-clavulanate Etest strip detected ESBL in an additional 13 (11.4%) isolates as compared to the other ESBL Etest strips. Conclusions: Cefepime-clavulanate ESBL Etest is a suitable substitute to test for ESBL production, especially in organisms producing AmpC beta-lactamases.

14 November 2013 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
SMSrujana Mohanty
Srujana Mohanty
VMVijeta Maurya
Vijeta Maurya
RGRajni Gaind
Rajni Gaind
MDMonorama Deb
Monorama Deb
Introduction: Pseudomonas aeruginosa and Acinetobcter spp. are important nosocomial pathogens and carbapenem resistance is an emerging threat. Therapeutic options for infections with these isolates include colistin. This study was conducted to determine the prevalence of carbapenem resistance in P. aeruginosa and Acinetobacter spp. bloodstream isolates, phenotypically characterize the resistance mechanisms and evaluate the invitro activity of colistin. Methodology: Consecutive 145 (95 P.aeruginosa and 50 Acinetobacter spp.) non-repeat isolates were included. Antibiotic susceptibility testing was performed per CLSI guidelines. MIC for carbapenems and colistin was performed using Etest. Isolates showing reduced susceptibility or resistance to the carbapenems were tested for metallo-β-lactamase (MBL) production using imipenem-EDTA combined disk and MBL Etest. Results: Carbapenem resistance was observed in 40% P. aeruginosa and 66.0% Acinetobacter spp. Carbapenem-resistant (CA-R) isolates were significantly (p< 0.05) more frequently resistant to the other antibiotics than carbapenem-susceptible isolates. Approximately half of the CA-R strains were multidrug-resistant, and 3.1-5.5% were resistant to all antibiotics tested. MBL was found in 76.3% and 69.7% of the P. aeruginosa and Acinetobacter spp., respectively. Colistin resistance was observed in three (6.0%) Acinetobacter isolates and eight (8.4%) P. aeruginosa. MIC50 for carbapenems were two to four times higher for MBL-positive compared to MBL-negative isolates, but no difference was seen in MIC for colistin. Conclusion: Carbapenem resistance was observed to be mediated by MBL in a considerable number of isolates. Colistin is an alternative for infections caused by CA-R isolates; however, MIC testing should be performed whenever clinical use of colistin is considered.

1 April 2023 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
BYBhuvan Yadav
Bhuvan Yadav
SMSrujana Mohanty
Srujana Mohanty
BBBijayini Behera
Bijayini Behera
Purpose: This study was conducted to find out the occurrence of hypervirulent Klebsiella pneumoniae (hvKP) isolates from different clinical specimens in a tertiary care hospital of eastern India and investigate the distribution of virulence factors, capsular serotypes and antibiogram profile. The distribution of carbapenemase-encoding genes in convergent (hvKP and carbapenem-resistant) isolates was also studied. Materials and methods: A total of 1004 K. pneumoniae isolates were obtained from different clinical specimens from August 2019 to June 2021 and hvKP isolates were identified using the string test. Genes of capsular serotypes K1, K2, K5, K20, K54 and K57, virulence-associated genes, rmpA, rmpA2, mrkD, allS, iroN, iutA, iuc, kfuB and ybtS, and carbapenemase-encoding genes, NDM-1, OXA-48, OXA-181, and KPC, were evaluated by polymerase chain reaction. Antimicrobial susceptibility was determined primarily by the VITEK-2 Compact automated platform (bioMérieux, Marcy-l’Étoile, France) and supplemented by disc-diffusion/EzyMIC (HiMedia, Mumbai, India) wherever needed. Results: Out of 1004 isolates, 33 (3.3%) were hvKP. Most frequent capsular serotype was K2 in 11 (33.3%). Amongst virulence genes, mrkD, iutA and kfuB were detected most frequently in 93.9%, 84.8% and 63.6% isolates respectively. Classical Klebsiella pneumoniae isolates were significantly more resistant than hvKP to cephalosporins, amoxicillin-clavulanic acid, and fluoroquinolones (p < 0.05). Carbapenem resistance was seen in 10 hvKP convergent isolates with the most prevalent carbapenemase-encoding gene being OXA-48 and OXA-181 in 50% isolates. Conclusion: There is a need for continued surveillance of hvKP strains in view of the impending threat of a global spread of convergent strains.

1 March 2005 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
PDF file
SMSrujana Mohanty
Srujana Mohanty
BDBenu Dhawan
Benu Dhawan
AKArti Kapil
Arti Kapil
BDBimal Kumar Das
Bimal Kumar Das
PPParitosh Pandey
Paritosh Pandey
Aditya K GuptaAditya K Gupta
Aditya K Gupta

6 July 2021 in Journal of Laboratory Physicians
Verified
Journal Article
Open access
PDF file
PKPunyatoya Kar
Punyatoya Kar
BBBijayini Behera
Bijayini Behera
SMSrujana Mohanty
Srujana Mohanty
JJJayanti Jena
Jayanti Jena
AMAshoka Mahapatra
Ashoka Mahapatra
Objective Challenges in susceptibility testing of colistin along with increase in the prevalence of colistin-resistant carbapenemase-producing Enterobacteriaceae (CRE) pathogens needs addressal. Evaluation of user-friendly methods is necessary as an alternative to broth microdilution (BMD), the reference susceptibility testing method, for routine implementation in diagnostic clinical microbiology laboratories. Genotypic detection of the plasmid-mediated colistin resistance is also needed for infection control purposes. Materials and Methods Colistin susceptibility of 200 nonduplicate clinical CRE isolates from December 2017 to June 2019 was determined by BMD, agar dilution (AD), E test, and rapid polymyxin NP test and interpreted as per the European Committee on Antimicrobial Susceptibility Testing. The results of AD, E test, and NP test were compared with that of BMD, considering minimal inhibitory concentration (MIC) ≤ 2 µg/mL as susceptible and > 2 µg/mL as resistant. Presence of any plasmid-mediated colistin resistance (mcr-1 and 2) was evaluated in 27 colistin-resistant CRE isolates by polymerase chain reaction. Statistical Analysis Performance of different phenotypic methods was analyzed by comparing MIC results of AD and E test with that of reference BMD method. Agreement between BMD and the other two methods was expressed in terms of categorical agreement and essential agreement. Errors were expressed as very major error (VME: false-susceptible) and major error (ME: false-resistance) by AD/E test. VME and ME of 3% disagreement were considered unacceptable. Results Colistin resistance was found in 27 (13.5%) isolates by BMD method. The VME rates of both AD (11%) and E test (37%) could not meet the Clinical and Laboratory Standards Institute recommendation (< 3% VME rate is acceptable) as alternative tests to the reference BMD. Colistin NP test showed sensitivity and specificity of 85% and 98%, respectively. The percentage discordant result in NP test was highest in Enterobacter spp. (17%). None of the 27 colistin resistant isolates showed presence of mcr-1 and mcr-2 genes. Conclusion High VME rate in AD and E tests precludes their use as alternatives to BMD for colistin susceptibility testing. NP test with moderate sensitivity but excellent specificity can be a good alternative for testing colistin susceptibility in CRE isolates, except in Enterobacter spp. Absence of mcr-1 and mcr-2 gene necessitates the exploration of other mechanisms of colistin resistance.

1 October 2019 in Journal of Laboratory Physicians
Verified
Journal Article
Open access
PDF file
SMSrujana Mohanty
Srujana Mohanty
BBBijayini Behera
Bijayini Behera
SSSubhrajyoti Sahu
Subhrajyoti Sahu
APAshok Kumar Praharaj
Ashok Kumar Praharaj
PURPOSE: We aimed to determine the recent pattern of antibiotic resistance and assess the vancomycin susceptibility profile of clinical Staphylococcus aureus in view of emerging reports of vancomycin creep, reduced vancomycin susceptibility (RVS), including heterogeneous vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus, and vancomycin resistance in S. aureus isolates. MATERIALS AND METHODS: Consecutive, nonduplicate isolates of S. aureus between July 2015 and June 2016 were subjected to antimicrobial susceptibility testing using standard disk diffusion test or Etest as per the Clinical and Laboratory Standards Institute 2015. Detection of hVISA was done by glycopeptide resistance detection Etest according to the manufacturer's instructions in strains with vancomycin minimum inhibitory concentration of 1–2 μg/ml. RESULTS: A total of 284 S. aureus were obtained from pus (175, 61.6%), respiratory tract (31, 10.9%), urine (27, 9.5%), blood (25, 8.8%), body fluids (18, 6.3%), and catheter tips (8, 2.8%). 127 (44.7%) isolates were methicillin resistant, and 158 (55.6%) were multidrug resistant. High resistance was observed to penicillin (81.7%), erythromycin (62.3%), and ciprofloxacin (52.1%), whereas the resistance was low to gentamicin (5.3%), rifampicin (8.1%), and doxycycline (9.5%). Two hundred and fifty-one (88.3%) isolates were fully susceptible to vancomycin, whereas 33 (11.6%) demonstrated RVS. All were uniformly susceptible to linezolid, tigecycline, and daptomycin. CONCLUSIONS: A moderately high percentage of S. aureus isolates demonstrated RVS, which may limit its usefulness in methicillin-resistant isolates and may be associated with increased complications in methicillin-susceptible infections. In view of increasing glycopeptide resistance, the susceptibility status of vancomycin along with other antibiotics among clinical S. aureus isolates should be investigated periodically.